SCTX (Scribe Therapeutics) EBIT: $-16.52 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCTX Scribe Therapeutics Inc SCTX
8 GF Score
Price $22.00
View Full Analysis

What is Scribe Therapeutics EBIT?

Scribe Therapeutics SCTX -13.40% 8 EBIT is $-16.52 Mil as of Mar. 2026. GuruFocus rates SCTX with a GF Score™ of 8/100.

Scribe Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-16.52 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-16.52 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Scribe Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 was -62.67%. Scribe Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -681.70%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Scribe Therapeutics  (NAS:SCTX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Scribe Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-49.708 * ( 1 - 0% )/( (73.427 + 85.199)/ 2 )
=-49.708/79.313
=-62.67 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=78.219 - 6.915 - ( 57.963 - max(0, 69.057 - 66.934+57.963))
=73.427

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=65.208 - 7.33 - ( 49.731 - max(0, 79.72 - 52.399+49.731))
=85.199

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Scribe Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-66.084/( ( (10.072 + max(-30.812, 0)) + (9.316 + max(-36.7, 0)) )/ 2 )
=-66.084/( ( 10.072 + 9.316 )/ 2 )
=-66.084/9.694
=-681.70 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.621) - (6.915 + 21.087 + 4.431)
=-30.812

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.147) - (7.33 + 28.33 + 2.187)
=-36.7

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Scribe Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-16.521/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scribe Therapeutics EBIT Related Terms

Scribe Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Scribe Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scribe Therapeutics EBIT Chart

Scribe Therapeutics Annual Data
Trend Dec24 Dec25
EBIT
-35.18 -21.22

Scribe Therapeutics Quarterly Data
Dec24 Mar25 Dec25 Mar26
EBIT 0.00 -3.14 0.00 -16.52

SCTX vs : EBIT Comparison

For the Biotechnology subindustry, Scribe Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scribe Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scribe Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Scribe Therapeutics's EV-to-EBIT falls into.


SCTX
8GF Score
Scribe Therapeutics Inc SCTX
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scribe Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-16.52 Mil mean?
Scribe Therapeutics (SCTX) has a EBIT of $-16.52 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Scribe Therapeutics.
Is Scribe Therapeutics' EBIT too high?
Scribe Therapeutics' current EBIT is $-16.52 Mil. Overall, Scribe Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Scribe Therapeutics' EBIT compare to ?
Scribe Therapeutics' EBIT of $-16.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Scribe Therapeutics. Scribe Therapeutics's current EBIT is $-16.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scribe Therapeutics stock overvalued right now?
Scribe Therapeutics (SCTX) has a current EBIT of $-16.52 Mil. The current EBIT is $-16.52 Mil. Scribe Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Scribe Therapeutics (SCTX), the current EBIT is $-16.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scribe Therapeutics Business Description

Comparable Companies
Address 1150 Marina Village Parkway, Alameda, CA, USA, 94501
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
8GF Score

Get the complete analysis for SCTX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.00
Price